LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) declared a quarterly dividend on Tuesday, October 27th. Investors of record on Thursday, November 19th will be paid a dividend of $0.25 per share by the medical instruments supplier on Thursday, December 3rd. This represents a $1.00 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date is Thursday, November 19th.
LeMaitre Vascular has raised its dividend by an average of 0.2% annually over the last three years and has raised its dividend annually for the last 14 consecutive years. LeMaitre Vascular has a dividend payout ratio of 42.0% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect LeMaitre Vascular to earn $3.15 per share next year, which means the company should continue to be able to cover its $1.00 annual dividend with an expected future payout ratio of 31.7%.
LeMaitre Vascular Price Performance
NASDAQ LMAT opened at $77.01 on Tuesday. The company has a market capitalization of $1.76 billion, a PE ratio of 28.00, a price-to-earnings-growth ratio of 2.29 and a beta of 0.51. LeMaitre Vascular has a 12-month low of $76.60 and a 12-month high of $118.01. The firm’s 50 day moving average is $81.24 and its 200-day moving average is $93.91. The company has a quick ratio of 12.54, a current ratio of 14.60 and a debt-to-equity ratio of 0.39.
LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.69 by ($0.04). LeMaitre Vascular had a return on equity of 15.33% and a net margin of 23.51%. The firm had revenue of $67.97 million for the quarter, compared to the consensus estimate of $67.39 million. During the same period last year, the company posted $0.75 earnings per share. The business’s revenue was up 11.3% compared to the same quarter last year. Equities research analysts anticipate that LeMaitre Vascular will post 2.83 earnings per share for the current fiscal year.
Institutional Investors Weigh In On LeMaitre Vascular
Several large investors have recently modified their holdings of LMAT. BlackRock Inc. purchased a new stake in shares of LeMaitre Vascular during the second quarter valued at approximately $314,075,000. Advisors Asset Management Inc. purchased a new stake in LeMaitre Vascular in the third quarter worth about $49,581,000. Boston Trust Walden Corp purchased a new position in shares of LeMaitre Vascular in the 3rd quarter valued at approximately $28,546,000. Ranger Investment Management L.P. bought a new stake in LeMaitre Vascular during the second quarter worth about $21,045,000. Finally, Voya Investment Management LLC boosted its holdings in LeMaitre Vascular by 1,116.5% in the third quarter. Voya Investment Management LLC now owns 238,914 shares of the medical instruments supplier’s stock worth $19,732,000 after acquiring an additional 219,274 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.
LeMaitre Vascular Company Profile
LeMaitre Vascular develops, manufactures and markets medical devices used primarily in the treatment of vascular disease. Its products support procedures performed by vascular surgeons and include vascular grafts, embolectomy catheters, carotid shunts, valvulotomes and other instruments used in vascular surgery. Founded in 1983 by vascular surgeon George LeMaitre, the company is headquartered in Burlington, Massachusetts. Its products are sold to hospitals and medical professionals around the world through a combination of direct sales and distributors.
Featured Articles
- Five stocks we like better than LeMaitre Vascular
- Microsoft’s Outage Barely Moved Its Stock, But a Bigger Risk May Be Building
- MongoDB’s Biggest Advantage May Be GitLab’s Biggest Weakness
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.
